Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Classical hematology 1

Conditions

Anemia, Refractory, with Excess of Blasts 14Myelodysplastic Syndromes 13Leukemia, Myeloid, Acute 13Neoplasms 10Anemia 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Venous Thromboembolism 6Myeloproliferative Disorders 6Thrombocytopenia 5Leukemia, Myelomonocytic, Chronic 5Anemia, Aplastic 5Primary Myelofibrosis 4Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, Non-Hodgkin 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hematologic Neoplasms 4Fanconi Anemia 4Burkitt Lymphoma 4Pulmonary Embolism 3Multiple Myeloma 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Biphenotypic, Acute 3Leukemia 3Hodgkin Disease 3Febrile Neutropenia 3Cytopenia 3Congenital Bone Marrow Failure Syndromes 3Blast Crisis 3

Interventions

thymoglobulin 1fludarabine 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Dexamethasone 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
beta-Thalassemia × Classical hematology × 30 days × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡